Models for Plasma Glucose, HbA1c, and Hemoglobin Interrelationships in Patients with Type 2 Diabetes Following Tesaglitazar Treatment

This publication has 25 references indexed in Scilit:

• Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12‐week dose-ranging trial
  Current Medical Research and Opinion, 2006
• A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus
  Journal of Pharmacokinetics and Pharmacodynamics, 2006
• Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
  Nature Medicine, 2005
• Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population
  Diabetologia, 2005
• Population PKPD modelling of the long‐term hypoglycaemic effect of gliclazide given as a once‐a‐day modified release (MR) formulation
  British Journal of Clinical Pharmacology, 2003
• Thiazolidinediones
  Clinical Drug Investigation, 2002
• Plasma Glucose Levels Throughout the Day and HbA1c Interrelationships in Type 2 Diabetes
  Diabetes Care, 2001
• Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
  Computer Methods and Programs in Biomedicine, 1998
• The Clinical Information Value of the Glycosylated Hemoglobin Assay
  New England Journal of Medicine, 1984
• The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus
  Science, 1978